Nakatsukasa v. Furiex Pharms., Inc.

2015 NCBC 68
CourtNorth Carolina Business Court
DecidedJuly 1, 2015
Docket14-CVS-6156
StatusPublished

This text of 2015 NCBC 68 (Nakatsukasa v. Furiex Pharms., Inc.) is published on Counsel Stack Legal Research, covering North Carolina Business Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nakatsukasa v. Furiex Pharms., Inc., 2015 NCBC 68 (N.C. Super. Ct. 2015).

Opinion

Nakatsukasa v. Furiex Pharms., Inc., 2015 NCBC 68.

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE SUPERIOR COURT DIVISION COUNTY OF WAKE 14 CVS 6156

WALTER NAKATSUKASA, Individually and ) on Behalf of All Others Similarly Situated, ) Plaintiff ) ) v. ) ) FURIEX PHARMACEUTICALS, INC., JUNE ) S. ALMENOFF, PETER B. CORR, ) STEPHEN R. DAVIS, WENDY L. DIXON, ) FREDRIC N. ESHELMAN, STEPHEN W. ) KALDOR, ROYAL EMPRESS, INC. and ) FOREST LABORATORIES, INC., ) Defendants )

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE SUPERIOR COURT DIVISION COUNTY OF WAKE 14 CVS 6955

CHRISTOPHER SHINNEMAN, Individually ) and on Behalf of All Others Similarly ) Situated, ) Plaintiff ) ) v. ) ) FURIEX PHARMACEUTICALS, INC., ) FREDRIC N. ESHELMAN, JUNE S. ) ALMENOFF, PETER B. CORR, WENDY L. ) DIXON, STEPHEN W. KALDOR, STEPHEN ) R. DAVIS, ROYAL EMPRESS, INC. and ) FOREST LABORATORIES, INC., ) Defendants )

ORDER FINALLY APPROVING SETTLEMENT AND AWARDING ATTORNEYS' FEES

THIS MATTER comes before the Court on Plaintiffs' Motion for Final Approval of

Settlement ("Approval Motion") and Motion for Award of Attorneys' Fees and Expenses ("Fee

Motion," together with Approval Motion, "Motions"). Both Motions are unopposed by

Defendants, and the Court, after appropriate notice to potential class members was provided as required by the Court's Order Preliminarily Approving Settlement, received no objection

to the settlement conditionally entered on or about January 15, 2015 ("Settlement"). On June

2, 2015, the Court held a hearing on the Motions and is satisfied as to the fairness,

reasonableness, and adequacy of the Settlement, and the fairness and reasonableness of the

fees, costs, and incentives provided herein. Therefore, the Court GRANTS the Approval

Motion, CERTIFIES the class as defined below for settlement purposes only, APPROVES the

Settlement, and GRANTS, in part, the Fee Motion for the reasons below.

Rabon Law Firm, PLLC, by Gary W. Jackson, Esq., and Brodsky & Smith, LLC by Evan J. Smith, Esq. for Plaintiffs.

Wyrick Robbins Yates & Ponton, LLP by Lee M. Whitman, Esq. for Defendants Furiex Pharmaceuticals, Inc., June S. Almenoff, Peter B. Corr, Stephen R. Davis, Wendy L. Dixon, Fredric N. Eshelman, Stephen W. Kaldor.

Robinson, Bradshaw & Hinson, P.A. by Adam K. Doerr, Esq., David C. Wright, III, Esq., and Robert W. Fuller, Esq., and Covington & Burling LLP by Mark P. Gimbel, Esq. and Christopher Y.L. Yeung, Esq. for Defendants Forest Laboratories, Inc. and Royal Empress, Inc.

McGuire, Judge.

Background

1. Plaintiffs in these actions, Walter Nakatsukasa and Christopher Shinneman,

are former shareholders of Furiex Pharmaceuticals, Inc. ("Furiex").

2. On April 28, 2014, Furiex announced that it had entered into an Agreement

and Plan of Merger ("Merger Agreement") with Forest Laboratories, Inc. ("Forest") and Royal

Empress, Inc. Pursuant to the terms of the Merger Agreement, Furiex shareholders would

have the right to receive $95.00 per share plus a Contingent Value Right of up to $30 per

share in exchange for their Furiex shares.

3. Following the announcement of the Merger, four putative class-action lawsuits

challenging the Merger were filed, all of which the parties agree arise from the same set of

operative facts and involve the same putative class: Kollman v. Furiex Pharmaceuticals, Inc. et al., Case No. 9599, and Powell v. Furiex Pharmaceuticals, Inc. et al., Case No. 9603, filed

on May 1 and 2, 2014, respectively, in the Court of Chancery of the State of Delaware

(together, the “Delaware Actions”); the Nakatsukasa Action, filed on May 12, 2014; and the

Shinneman Action, filed on May 28, 2014 (together, the “North Carolina Actions” and

together with the Delaware Actions, the “Actions”).

4. On June 4, 2014, Furiex filed its Definitive Proxy Statement on Schedule 14A

("Proxy") with the Securities and Exchange Commission ("SEC"). On the same date, Plaintiffs

in all four actions filed substantively identical amended complaints. The amended complaints

alleged, among other disclosure issues, that the Proxy failed to disclose whether

confidentiality agreements entered into between Furiex and potential buyers contained

standstill or "don't ask, don't waive" provisions ("DADW provisions").

5. On June 11, 2014, the parties to the North Carolina actions agreed to an

expedited discovery schedule which included an agreement to stay all further proceedings in

the Delaware Actions. After reviewing documents produced during this expedited discovery,

Plaintiffs' concluded that five confidentiality agreements entered into between Furiex and

potential buyers contained DADW provisions. Additionally, Plaintiffs determined that the

Proxy failed to provide Furiex shareholders with "material information concerning, among

other things, the process which resulted in the [m]erger, Furiex's financial projections, and

the financial analyses by [Bank of America Merrill Lynch ("BAML")] and Credit Suisse

Securities (USA) LLC [("Credit Suisse")] underlying each advisor's fairness opinion."1

6. As part of the resolution of this matter, Furiex notified the parties to the five

DADW provisions that it would waive those provisions. Having resolved the DADW issue,

Plaintiffs' counsel engaged in vigorous, arm's-length negotiations which ultimately resulted

1 Pls.' Mem. Supp. Mot. Prelim. Approval of Settlement 3-4. in the execution of a Memorandum of Understanding on June 23, 2014. In addition to waiving

the DADW provisions, the negotiated settlement provided Furiex shareholders with

supplemental disclosures that Plaintiffs believed resolved their remaining claims. On June

23, 2014, Furiex filed these supplemental disclosures on Schedule 14A with the SEC.

7. On July 1, 2014, Furiex stockholders voted to approve the Merger.

Approximately 79.86% of Furiex’s outstanding common stock was voted at the meeting, of

which a majority voted in favor of the Merger.

8. On January 15, 2015, the parties executed a Stipulation and Agreement of

Compromise, Settlement, and Release ("Stipulation"), and on February 9, 2015, Plaintiffs

filed their Unopposed Motion for Preliminary Approval of Settlement, Certification of

Settlement Class, Approval of Class Notice and Final Approval Hearing Scheduling. On

March 23, 2015, the Court entered its Order Preliminarily Approving Settlement and

Providing for Notice ("Preliminary Approval Order"), and noticed a hearing for approval of

the final settlement for June 3, 2015. The parties subsequently provided written notice to

class members advising them, inter alia, of their rights to object to the proposed settlement.

Neither the Court nor the parties received any objection to the Settlement, either before,

during, or after the June 3 hearing.

9. On May 22, 2015, Plaintiff filed the Motions, along with supporting affidavits

and other materials. On June 3, 2015 the Court held a hearing on the motions for final

approval and for attorneys’ fees.

Class Certification

10. Rule 23 of the North Carolina Rules of Civil Procedure ("Rule(s)") governs class

actions. Under that rule, the trial court has broad discretion in determining whether to certify

a case as a class action. Harrison v. Wal-Mart Stores, Inc., 170 N.C. App. 545, 547 (2005).

The Court, in its discretion, may certify a class action if certain requirements are satisfied.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pitts v. American Security Insurance
550 S.E.2d 179 (Court of Appeals of North Carolina, 2001)
Stillwell Enterprises, Inc. v. Interstate Equipment Co.
266 S.E.2d 812 (Supreme Court of North Carolina, 1980)
United Laboratories, Inc. v. Kuykendall
437 S.E.2d 374 (Supreme Court of North Carolina, 1993)
Harrison v. Wal-Mart Stores, Inc.
613 S.E.2d 322 (Court of Appeals of North Carolina, 2005)
In Re Wachovia Shareholders Litigation
607 S.E.2d 48 (Court of Appeals of North Carolina, 2005)
Sala v. National Railroad Passenger Corp.
721 F. Supp. 80 (E.D. Pennsylvania, 1989)
In Re Netsmart Technologies, Inc. Shareholders Litigation
924 A.2d 171 (Court of Chancery of Delaware, 2007)
Ehrenhaus v. Baker
717 S.E.2d 9 (Court of Appeals of North Carolina, 2011)
In re Pure Resources, Inc., Shareholders Litigation
808 A.2d 421 (Court of Chancery of Delaware, 2002)
In re Sauer-Danfoss Inc. Shareholders Litigation
65 A.3d 1116 (Court of Chancery of Delaware, 2011)
Beroth Oil Co. v. North Carolina Department of Transportation
757 S.E.2d 466 (Supreme Court of North Carolina, 2014)
Ge Betz, Inc. v. Conrad
752 S.E.2d 634 (Court of Appeals of North Carolina, 2013)
In Re Progress Energy Shareholder Litigation
2011 NCBC 44 (North Carolina Business Court, 2011)
In Re Harris Teeter Merger Litig.
2014 NCBC 44 (North Carolina Business Court, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
2015 NCBC 68, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nakatsukasa-v-furiex-pharms-inc-ncbizct-2015.